61 results about "HL - Hearing loss" patented technology

The present invention relates to the prophylaxis of acute noise-induced hearing loss by administering a compound of formula (I): wherein: W is group (Wa), group (Wb) or group (Wc):

Polyamidoamine, its partially degraded products or its complexes-Math1 gene nanoparticles, method for preparing the same and use thereof, the gene nanoparticles can be produced through complex coacervating of polyamidoamine, or polyamidoamine complexes and a Math1 gene-containing plasmid. The gene nanoparticles are controllable in particle size, uniform in size, favorable for surface modification, can enhance the ability of expression and delivery of the Math1 gene, and is useful in a sensorineural hearing loss caused by hair cells loss due to noise, drug toxicity etc.

Methods and compositions using an inhibitor of EGFR signaling for prevention or an inhibitor of EGFR signaling and a nucleic acid molecule encoding an atonal-associated factor for treatment of hearingloss are described.

A system and a method for a healthcare provider to easily, accurately and efficiently provide a hearing test and a pressure test, i.e., a hearing assessment, for their patients, in a way that accurately detects hearing loss and provides recommendations for seeking further assistance from qualified hearing health specialists is provided.

The present invention relates to the prophylaxis of acute noise-induced hearing loss by administering a compound of formula (I): wherein: W is group (Wa), group (Wb) or group (Wc):

A system and a method for a healthcare provider to easily, accurately and efficiently provide a diagnostic hearing assessment, for their patients, in a way that accurately detects hearing loss and provides recommendations for seeking further assistance from remotely-located ear specialists is provided.

The invention provides an SLC26A4 gene mutant and application thereof. The invention provides a gene mutation. Compared with a wild type SLC26A4 gene, the gene mutation has c.128delG mutation and / or (formula sees the description) mutation. The gene mutation is detectable, and whether a biological sample suffers from non-syndrome deafness can be effectively detected by detecting whether the gene mutation exists in the biological sample. By detecting the gene mutation, detection and research of hereditary hearing loss diseases are expanded and perfected, and a new detection site and a new detection method and way are provided for diagnosis or treatment of the diseases.

A composition and method of treatment of neuromuscular, neuromuscular degenerative, neurodegenerative, autoimmune, developmental, traumatic, hearing loss related, and / or metabolic diseases, including spinal muscular atrophy (SMA) syndrome (SMA1, SMA2, SMA3, and SMA4, also called Type I, II, III and IV), traumatic brain injury (TBI), concussion, keratoconjunctivitis sicca (Dry Eye Disease), glaucoma, Sjogren's syndrome, rheumatoid arthritis, post-LASIK surgery, anti-depressants use, Wolfram Syndrome, and Wolcott-Rallison syndrome. The composition is selected from the group consisting of 2,3-DNP, 2,4-DNP, 2,5-DNP, 2,6-DNP, 3,4-DNP, or 3,5-DNP, bipartite 2,3-dinitrophenol, 2,4-dinitrophenol, 2,5-dinitrophenol, 2,6-dinitrophenol, 3,4-dinitrophenol, or 3,5-dinitrophenol (2,3-DNP, 2,4-DNP, 2,5-DNP, 2,6-DNP, 3,4-DNP, or 3,5-DNP) prodrugs; Gemini prodrugs, bioprecursor molecules, and combinations thereof. A dose of the composition for treatment of neurodegenerative diseases may be from about 0.01 mg / kg of body weight to about 50 mg / kg of body weight of the patient in need of treatment. A dose of the composition for treatment of metabolic diseases may be from about 1 mg / 70 kg of body weight to about 100 mg / 70 kg of body weight of the patient in need of treatment, and a maximum dose per day is about 200 mg / 70 kg of body weight of the patient in need of treatment.

The present invention relates to a composition including a naphthoquinone compound for treating and preventing hearing loss.